KRAS and non-small cell lung carcinoma: Since NSCLC is composed of many genomic subsets, each with its own driver mutation, research efforts were made to develop therapeutic drugs that selectively target a specific driver mutation such as KRAS, epidermal growth factor receptor (EGFR), BRAF, and anaplastic lymphoma kinase (ALK).